Get regular updates to your inbox.
For one in three people with neuromyelitis optica spectrum disorder (NMOSD), bad days — marked by high levels of debilitating symptoms — are more common than good days. Patients who are more comfortable talking with their doctors about their symptoms reported fewer bad days and greater treatment…
Ad Scientiam is developing new digital biomarkers of neuromyelitis optica spectrum disorder (NMOSD) that may allow continuous and remote monitoring of patients’ symptoms over time. The Paris-based software company announced the program launch along with a similar one for people with generalized myasthenia gravis, another rare autoimmune…
The annual prevalence of neuromyelitis optica spectrum disorder (NMOSD) in the U.S. is considerably higher than previously estimated, affecting about nine out of every 100,000 people, according to a study that analyzed 2021 electronic health records. The data also showed that the disease is more than twice as common…
Uplizna (inebilizumab) does not increase the risk of COVID-19 infection or reduce the levels of antibodies produced from prior childhood vaccines among people with neuromyelitis optica spectrum disorder (NMOSD). That’s according to two posterior analyses of data from the Phase 2/3 N-MOmentum clinical trial (NCT02200770) after the…
March is NMOSD Awareness Month and patients and advocates are planning several initiatives to put a new focus on the progressive autoimmune disease, known fully as neuromyelitis optica spectrum disorder. Affecting more than 25,000 people worldwide, NMOSD is a disorder characterized by inflammation of the optic nerve — the…
More than a third of people with neuromyelitis optica spectrum disorder (NMOSD) show cognitive impairment, particularly in visual processing speed and verbal domains, according to a large study in Germany. This cognitive impairment was independent of disease duration and remained constant over two years of follow-up. It also did…
A rare case of neuromyelitis optica spectrum disorder (NMOSD) in a patient positive for antibodies against both aquaporin-4 (AQP4) protein and the myelin oligodendrocyte glycoprotein (MOG) was successfully treated with ofatumumab, a B-cell depleting medication approved for multiple sclerosis (MS), a case study reported. According to its researchers, this case represents…
People with neuromyelitis optica spectrum disorder (NMOSD) have a significantly higher neutrophil-to-lymphocyte ratio (NLR), an immune cell-based marker of inflammation, than healthy people, a review study showed. A higher NLR ratio was also significantly associated with a greater chance of relapse, severe disability, and new or enlarging lesions on…
Ofatumumab, a medication approved for multiple sclerosis (MS), effectively prevented relapses and disability progression in a 67-year old woman with neuromyelitis optica spectrum disorder (NMOSD) who failed to respond to rituximab, a Chinese case report described. Both ofatumumab and rituximab — often used off-label in NMOSD — promote the…
Undergoing plasma exchange, a blood-cleaning procedure, within 10 days after a relapse of neuromyelitis optica spectrum disorder (NMOSD) may help ease symptoms in children positive for antibodies against AQP4 and who do not respond well to corticosteroids. That’s according to a small study that assessed the safety and efficacy…
Get regular updates to your inbox.